Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Structural and regulatory diversity shape HLA-C protein expression levels.

Kaur G, Gras S, Mobbs JI, Vivian JP, Cortes A, Barber T, Kuttikkatte SB, Jensen LT, Attfield KE, Dendrou CA, Carrington M, McVean G, Purcell AW, Rossjohn J, Fugger L.

Nat Commun. 2017 Jun 26;8:15924. doi: 10.1038/ncomms15924.

2.

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.

Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, Compston A, Johnson AR, Everett C, Bell JI, Karpe F, Ultsch M, Eigenbrot C, McVean G, Fugger L.

Sci Transl Med. 2016 Nov 2;8(363):363ra149.

3.

Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor.

Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K.

Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(4):e241. doi: 10.1212/NXI.0000000000000241. eCollection 2016 Aug.

4.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

5.

CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis.

Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, Piedavent M, Friese MA.

Eur J Immunol. 2014 Oct;44(10):3119-28. doi: 10.1002/eji.201344160. Epub 2014 Aug 19.

6.

TCR transgenic mice that shed light on immune and environmental regulators in multiple sclerosis.

Attfield KE, Fugger L.

J Immunol. 2013 Apr 1;190(7):3015-7. doi: 10.4049/jimmunol.1300427. No abstract available.

7.

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.

Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L.

Nature. 2012 Aug 23;488(7412):508-511. doi: 10.1038/nature11307.

8.

Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis.

Attfield KE, Dendrou CA, Fugger L.

Immunol Rev. 2012 Jul;248(1):10-22. doi: 10.1111/j.1600-065X.2012.01132.x. Review.

PMID:
22725951
9.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ.

Blood. 2008 Nov 15;112(10):4170-7. doi: 10.1182/blood-2008-04-149161. Epub 2008 Jun 26.

10.

Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells.

Taraban VY, Martin S, Attfield KE, Glennie MJ, Elliott T, Elewaut D, Van Calenbergh S, Linclau B, Al-Shamkhani A.

J Immunol. 2008 Apr 1;180(7):4615-20.

Supplemental Content

Loading ...
Support Center